Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL
出版年份 2014 全文链接
标题
Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL
作者
关键词
-
出版物
BLOOD
Volume 125, Issue 9, Pages 1444-1451
出版商
American Society of Hematology
发表日期
2014-12-13
DOI
10.1182/blood-2014-09-601062
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
- (2015) Kathryn G. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo
- (2014) P. Gallipoli et al. BLOOD
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
- (2014) Matthew S. Zabriskie et al. CANCER CELL
- Stage-specific control of early B cell development by the transcription factor Ikaros
- (2014) Tanja A Schwickert et al. NATURE IMMUNOLOGY
- Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia
- (2013) B. Koss et al. BLOOD
- Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
- (2013) S. Soverini et al. BLOOD
- Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy
- (2013) F. Ravandi et al. BLOOD
- Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the fr
- (2013) Simona Soverini et al. CANCER
- Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2011) N. Boulos et al. BLOOD
- Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2011) R. Foa et al. BLOOD
- First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
- (2010) F. Ravandi et al. BLOOD
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- Glucocorticoid use in acute lymphoblastic leukaemia
- (2010) Hiroto Inaba et al. LANCET ONCOLOGY
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment
- (2009) J. S. Lagas et al. CLINICAL CANCER RESEARCH
- Pre–B cell receptor–mediated cell cycle arrest in Philadelphia chromosome–positive acute lymphoblastic leukemia requiresIKAROSfunction
- (2009) Daniel Trageser et al. JOURNAL OF EXPERIMENTAL MEDICINE
- P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib
- (2009) Y. Chen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL
- (2008) C. G. Mullighan et al. GENES & DEVELOPMENT
- BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
- (2008) Charles G. Mullighan et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started